Biomarkeri oksidativnog stresa i metabolički biomarkeri kod pacijenata obolelih od psorijaze
Oksidativni stres i psorijaza
Sažetak
Uvod i cilj: Psorijaza je autoinflamatorno oboljenje koje zahvata ne samo kožu, već i brojne organe i povezano je sa brojnim komorbiditetima. Oksidativni stres i inflamacija igraju glavnu ulogu u patogenezi ovog oboljenja. Kada su u pitanju biomarkeri oksidativnog stresa, studije pokazuju oprečne rezultate. Stoga je cilj ovog istraživanja bio da se ispita potencijalna povezanost biomarkera oksidativnog stresa, inflamacije i metaboličkih parametara sa težinom bolesti kod pacijenata sa psorijazom.
Metode: Ova studija slučajeva i kontrola obuhvatila je 35 pacijenata sa psorijazom, koliko i zdravih ispitanika uparenih po godinama starosti, polu i indeksu telesne mase. Metabolički i biomarkeri oksidativnog stresa [tj., malondialdehid (MDA), produkti uznapredoovale oksidacije proteina (AOPP) i katalaza (CAT)] su mereni. Analiza glavnih komponenti (PCA) je primenjena da smanji broj varijabli u manje grupe faktora.
Rezultati: Veće vrednosti AOPP (p<0,01) i aktivnosti CAT (p<0,001), bez postojanja razlike u MDA vrednostima uočene su kod pacijenata sa psorijazom u poređenju sa kontrolnom grupom. Multivarijantna binarna logistička regresiona analiza pokazala je da je kombinacija metaboličkih faktora (tj., glukoze i triglicerida) i renalnih faktora (tj., kreatinin i urea) najbolji model koji predviđa Psoriasis Area and Severity Indeksa (PASI) >10, dok je oksidativni stres-hepatični faktor (tj., MDA i alanin aminotransferaza) najbolji prediktor Dermatology Life Quality Indeksa (DLQI) >20.
Zaključak: “Multimarker” pristup (metabolički, renalni i oksidativni stres-hepatični faktor) se pokazao boljim prediktorom težine bolesti kod pacijenata obolelih od psorijaze nego bilo koji pojedinačni ispitivani biomarker.
Reference
1. Luo L, Guo Y, Chen L, Zhu J, Li C. Crosstalk between cholesterol metabolism and psoriatic inflammation. Front Immunol 2023; 14: 1124786. doi: 10.3389/fimmu.2023.1124786.
2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31(2): 205-212. doi: 10.1111/jdv.13854.
3. Medovic MV, Jakovljevic VL, Zivkovic VI, Jeremic NS, Jeremic JN, Bolevich SB, Ravic Nikolic AB, Milicic VM, Srejovic IM. Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches. Oxid Med Cell Longev 2022; 2022: 2249834. doi: 10.1155/2022/2249834.
4. Dobrică EC, Cozma MA, Găman MA, Voiculescu VM, Găman AM. The Involvement of Oxidative Stress in Psoriasis: A Systematic Review. Antioxidants (Basel) 2022; 11(2): 282. doi: 10.3390/antiox11020282.
5. Cannavò SP, Riso G, Casciaro M, Di Salvo E, Gangemi S. Oxidative stress involvement in psoriasis: a systematic review. Free Radic Res 2019; 53(8): 829-840. doi: 10.1080/10715762.2019.1648800.
6. Mohamed Haris NH, Krishnasamy S, Chin K-Y, Mariappan V, Arumugam M. Metabolic Syndrome Screening and Nutritional Status of Patients with Psoriasis: A Scoping Review. Nutrients 2023; 15(12): 2707. https://doi.org/10.3390/nu15122707
7. Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network? J Dtsch Dermatol Ges 2021; 19(4): 517-528. doi: 10.1111/ddg.14425.
8. Jing X, Zhuyuan W, Aijun C, Jianxia X, Kun H, Ping W. Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10: 1175477. doi: 10.3389/fmed.2023.1175477.
9. Kızılyel O, Akdeniz N, Metin MS, Elmas ÖF. Investigation of oxidant and antioxidant levels in patients with psoriasis. Turk J Med Sci 2019; 49(4): 1085-1088. doi: 10.3906/sag-1807-257.
10. Yildirim M, Inaloz HS, Baysal V, Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003; 17(1):34-36. doi: 10.1046/j.1468-3083.2003.00641.x.
11. Sikar Aktürk A, Özdoğan HK, Bayramgürler D, Çekmen MB, Bilen N, Kıran R. Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients. J Eur Acad Dermatol Venereol. 2012; 26(7): 833-837. doi: 10.1111/j.1468-3083.2011.04164.x.
12. Kirmit A, Kader S, Aksoy M, Bal C, Nural C, Aslan O. Trace elements and oxidative stress status in patients with psoriasis. Postepy Dermatol Alergol 2020; 37(3): 333-339. doi: 10.5114/ada.2020.94265.
13. Shakoei S, Nakhjavani M, Mirmiranpoor H, Motlagh MA, Azizpour A, Abedini R. The Serum Level of Oxidative Stress and Antioxidant Markers in Patients with Psoriasis: A Cross-sectional Study. J Clin Aesthet Dermatol 2021; 14(7): 38-41.
14. Yazici C, Köse K, Utaş S, Tanrikulu E, Taşlidere N. A novel approach in psoriasis: first usage of known protein oxidation markers to prove oxidative stress. Arch Dermatol Res 2016; 308(3): 207-212. doi: 10.1007/s00403-016-1624-0.
15. He L, Qin S, Dang L, Song G, Yao S, Yang N, Li Y. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. Biochim Biophys Acta 2014; 1841(12): 1709-1715. doi: 10.1016/j.bbalip.2014.09.008.
16. Wójcik P, Gęgotek A, Wroński A, Jastrząb A, Żebrowska A, Skrzydlewska E. Effect of redox imbalance on protein modifications in lymphocytes of psoriatic patients. J Biochem 2020; 167(3): 323-331. doi: 10.1093/jb/mvz096.
17. Esmaeili B, Mansouri P, Doustimotlagh AH, Izad M. Redox imbalance and IL-17 responses in memory CD4+ T cells from patients with psoriasis. Scand J Immunol 2019; 89(1): e12730. doi: 10.1111/sji.12730.
18. Skoie IM, Dalen I, Omdal R, Jonsson G. Malondialdehyde and advanced oxidation protein products are not increased in psoriasis: a controlled study. Arch Dermatol Res. 2019; 311(4): 299-308. doi: 10.1007/s00403-019-01903-2.
19. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
20. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49(5): 1304-1313. http://dx.doi.org/10.1038/ki.1996.186
21. Andreeva LI, Kozhemiakin LA, Kishkun AA. Modification of the method of determining lipid peroxidation in a test using thiobarbituric acid. Lab Delo 1988; (11): 41-43.
22. Góth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 1991; 196 (2–3): 143-151.
23. Klisic A, Kavaric N, Vujcic S, Spasojevic-Kalimanovska V, Kotur-Stevuljevic J, Ninic A. Factorial analysis of the cardiometabolic risk influence on redox status components in adult population. Oxid Med Cell Longev 2021; ID: 6661940. https://doi.org/10.1155/2021/6661940.
24. Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T, Suenaga A, Otagiri M. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet 2006; 21(2): 140-146. doi: 10.2133/dmpk.21.140.
25. Klisic A, Malenica M, Kostadinovic J, Kocic G, Ninic A. Malondialdehyde as an independent predictor of body mass index in adolescent girls. J Med Biochem 2023; 42:1-8. doi: 10.5937/jomb0-39044.
26. Klisic A, Isakovic A, Kocic G, Kavaric N, Jovanovic M, Zvrko E, Skerovic V, Ninic A. Relationship between Oxidative Stress, Inflammation and Dyslipidemia with Fatty Liver Index in Patients with Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes 2018; 126(06): 371-378. doi: 10.1055/s-0043-118667.
27. Malenica M, Klisic A, Meseldzic N, Dujic T, Bego T, Kotur-Stevuljevic J. Principal component analysis of the oxidative stress, inflammation, and dyslipidemia influence in patients with different levels of glucoregulation. J Med Biochem 2023; 42:1-10. doi: 10.5937/jomb0-39636.
28. Vassalle C, Xiao J, Sabatino L. Editorial: Relationship Between Cardiovascular Disease and Other Chronic Conditions. Front Cardiovasc Med 2022; 9: 875551. doi: 10.3389/fcvm.2022.875551.
Sva prava zadržana (c) 2023 Aleksandra Klisic
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.